Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) EBIT: 2014-2024

Historic EBIT for Collegium Pharmaceutical (COLL) over the last 11 years, with Dec 2024 value amounting to $169.9 million.

  • Collegium Pharmaceutical's EBIT rose 78.21% to $62.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $157.0 million, marking a year-over-year decrease of 18.86%. This contributed to the annual value of $169.9 million for FY2024, which is 1.76% up from last year.
  • Per Collegium Pharmaceutical's latest filing, its EBIT stood at $169.9 million for FY2024, which was up 1.76% from $167.0 million recorded in FY2023.
  • Collegium Pharmaceutical's EBIT's 5-year high stood at $169.9 million during FY2024, with a 5-year trough of $17.6 million in FY2021.
  • For the 3-year period, Collegium Pharmaceutical's EBIT averaged around $123.4 million, with its median value being $167.0 million (2023).
  • Its EBIT has fluctuated over the past 5 years, first crashed by 68.65% in 2021, then skyrocketed by 401.10% in 2023.
  • Over the past 5 years, Collegium Pharmaceutical's EBIT (Yearly) stood at $56.2 million in 2020, then slumped by 68.65% to $17.6 million in 2021, then skyrocketed by 89.01% to $33.3 million in 2022, then soared by 401.10% to $167.0 million in 2023, then climbed by 1.76% to $169.9 million in 2024.